Eamonn Martin Quigley, MD

David M. Underwood Chair of Medicine in Digestive Disorders, Department of Medicine
Professor of Medicine, Institute for Academic Medicine
Director, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Dr. Eamonn M. M. Quigley, past president of the American College of Gastroenterology and the World Gastroenterology Organization, joined the faculty at Houston Methodist Hospital as head of its Gastroenterology and Hepatology division in 2013.

Prior to his move to Houston, Quigley was professor of medicine and human physiology and a principal investigator at the Alimentary Pharmabiotic Centre at the National University of Ireland in Cork. He is internationally known for his research on gastrointestinal motility disorders, primarily irritable bowel syndrome (IBS); gastroesophageal reflux disease (GERD); neurogastroenterology (the relationship between the central nervous system and the gut); the gut microbiome and probiotics in health and disease. A highlight of his ongoing research includes how bacteria in the digestive tract play a major role in pulling nutrients from food to nourish the body, as well as participating in protecting the body from disease.

IBS is the most common, chronic medical condition in the United States. Approximately 40 percent of those with IBS have symptoms severe or frequent enough to disrupt their daily lives. While the cause of IBS has not been clearly identified, Quigley’s clinical research suggests that an alteration of the normal gut bacteria flora may be a cause. His research team is working toward developing new biomarkers for IBS which would eventually lead to the development of new treatments. Quigley’s clinical interests focus on the use of probiotics for the treatment of IBS.

He has published more than 800 peer-reviewed articles, reviews, editorials, book chapters and case reports, mostly in the areas of gut motility, functional gastrointestinal disorders, and GERD. Quigley has received numerous international honors and awards. He served as Editor-in-Chief of the American Journal of Gastroenterology from 1997 to 2003.

Quigley received his medical degree from  University College Cork in Cork, Ireland; completed internal medicine residency in Glasgow, Scotland; and did GI fellowship training at the Mayo Clinic and the University of Manchester in England.  He served as the Chief of Gastroenterology at the University of Nebraska from 1991 to 1998 and as Dean of the Medical School in Cork, Ireland from 2000 to 2007.

Description of Research

Some of his pioneering research over the past several decades has included how the function of the gut is affected in a variety of diseases and conditions, including chronic liver disease, high-dose chemoradiotherapy, intestinal failure and transplantation, and Parkinson’s disease.

Areas Of Expertise

Gastroesophageal Reflux Esophageal disorders/dysphagia Gastrointestinal motility disorders Functional GI disorders Irritable bowel syndrome Gastroparesis Constipation Diarrheal disorders Celiac disease Intestinal & colonic disorders Inflammatory bowel disease/colitis/Crohn's disease General gastroenterology EGD and colonoscopy Capsule endoscopy
Education & Training

Clinical Fellowship , University of Manchester
Residency , Western Infirmary & Associates Hospital
Internship , St. Finbarr's Hospital
MD , National University of Ireland;

Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms
Allen, AP, Clarke, G, Cryan, JF, Quigley, EMM & Dinan, TG 2017, Current Medical Research and Opinion, vol 33, no. 7, pp. 1349-1351. DOI:

Irritable Bowel Syndrome: An Infectious Disease?
Quigley, EMM & Lembo, AJ 2017, Gastroenterology, vol 152, no. 5, pp. 936-938. DOI:

Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?
Quigley, EMM 2017, Nature Reviews Gastroenterology and Hepatology. DOI:

Bifidobacterium breve with a-linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat
Patterson, E, Wall, R, Lisai, S, Ross, RP, Dinan, TG, Cryan, JF, Fitzgerald, GF, Banni, S, Quigley, EM, Shanahan, F & Stanton, C 2017, Scientific Reports, vol 7, 43300. DOI:

What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
Quigley, EMM 2017, Clinical Liver Disease, vol 9, no. 2, pp. 52-54. DOI:

The gut response to food: a physiological perspective on food-induced gastrointestinal symptoms – it's not all allergy and intolerance!
Quigley, EMM 2017, Current Opinion in Gastroenterology. DOI:

Leptin modifies the prosecretory and prokinetic effects of the inflammatory cytokine interleukin-6 on colonic function in Sprague–Dawley rats
Buckley, MM, OBrien, R, Devlin, M, Creed, AA, Rae, MG, Hyland, NP, Quigley, EMM, McKernan, DP & OMalley, D 2016, Experimental Physiology, vol 101, no. 12, pp. 1477-1491. DOI:

Editorial: balancing fibre and FODMAPs in IBS - a 'rye' look at an old problem
Quigley, EMM 2016, Alimentary Pharmacology and Therapeutics, vol 44, no. 10, pp. 1134-1135. DOI:

Editorial: balancing fibre and FODMAPs in IBS – a ‘rye’ look at an old problem
Quigley, EMM 2016, Alimentary Pharmacology and Therapeutics, vol 44, no. 10, pp. 1134-1135. DOI:

Colonic ischemia: usual and unusual presentations and their management
Oglat, A & Quigley, EMM 2016, Current Opinion in Gastroenterology. DOI:

The Microbiome and the Liver: The Basics
Victor, DW & Quigley, EMM 2016, Seminars in Liver Disease, vol 36, no. 4, pp. 299-305. DOI:

The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome
Quigley, EMM, Abu-Shanab, A, Murphy, EF, Stanton, C & Monsour, HP 2016, Seminars in Liver Disease, vol 36, no. 4, pp. 312-316. DOI:

The Microbiome: What Will the Future Hold?
Monsour, HP & Quigley, EMM 2016, Seminars in Liver Disease, vol 36, no. 4, pp. 354-359. DOI:

Primary Biliary Cirrhosis and the Microbiome
Quigley, EMM 2016, Seminars in Liver Disease, vol 36, no. 4, pp. 349-353. DOI:

Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician
Iqbal, S & Quigley, EMM 2016, Current Gastroenterology Reports, vol 18, no. 9, 49. DOI:

Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators
Martin-Viñas, JJ & Quigley, EMM 2016, Journal of Digestive Diseases. DOI:

The intestinal microenvironment and functional gastrointestinal disorders
Barbara, G, Feinle-Bisset, C, Ghoshal, UC, Santos, J, Vanner, SJ, Vergnolle, N, Zoetendal, EG & Quigley, EM 2016, Gastroenterology, vol 150, no. 6, pp. 1305-1318e8. DOI:

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
Camilleri, M, Piessevaux, H, Yiannakou, Y, Tack, J, Kerstens, R, Quigley, EMM, Ke, MY, da Silva, S & Levine, A 2016, Digestive Diseases and Sciences, pp. 1-16. DOI:

Irritable bowel syndrome
Enck, P, Aziz, Q, Barbara, G, Farmer, AD, Fukudo, S, Mayer, EA, Niesler, B, Quigley, EMM, Rajilic-Stojanovic, M, Schemann, M, Schwille-Kiuntke, J, Simren, M, Zipfel, S & Spiller, RC 2016, Nature Reviews Disease Primers, vol 2, pp. 1-24. DOI:

Advancing treatment options for chronic idiopathic constipation
Quigley, EMM & Neshatian, L 2016, Expert Opinion on Pharmacotherapy, vol 17, no. 4, pp. 501-511. DOI: